Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.32 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618893 | 0.93 | NPC1 (0.42) | NPC1KMT2AMEN1POLBRAB9A | |
| SCHEMBL13618888 | 0.85 | NPC1 (0.34) | NPC1KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL13618897 | 0.82 | NPC1 (0.61) | NPC1KMT2AMEN1POLBRAB9A | |
| SCHEMBL13618887 | 0.82 | HDAC1 (0.36) | NPC1RAB9AHPGDSMN1; SMN2HSD11B1 | |
| SCHEMBL13618877 | 0.81 | HDAC1 (0.37) | NPC1KMT2AMEN1RAB9AHPGD | |
| SCHEMBL13618889 | 0.77 | LMNA (0.30) | — | |
| SCHEMBL13618895 | 0.77 | NPC1 (0.51) | NPC1KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL13618884 | 0.74 | LMNA (0.37) | NPC1KMT2AMEN1POLBRAB9A | |
| SCHEMBL13618875 | 0.73 | LMNA (0.39) | NPC1KMT2AMEN1POLBRAB9A | |
| SCHEMBL13618890 | 0.69 | NPC1 (0.42) | NPC1KMT2AMEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | NPC1 151/4885KMT2A 1209/4885MEN1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.